Mpox
Mpox is a viral infection caused by monkeypox virus. It can spread from animals to people, and also from person to person through close contact. In the large 2022 global outbreak, spread was mainly linked to sexual contact among men who have sex with men. WHO also reported sustained person-to-person spread of clade I mpox in eastern Democratic Republic of the Congo in 2024. Illness often starts with fever, swollen lymph nodes, and a rash or sores that crust over. Many people recover in a few weeks, but severe disease and death can happen, especially in young children, pregnant people, and people with weakened immune systems. Severity differs by setting and outbreak: WHO reported a case fatality rate of 4.9% in the Democratic Republic of the Congo in 2024, 4.5% there in 2023, and 15% in a small South Africa outbreak in 2024. Vaccines and antiviral treatments exist in some places, but WHO reported shortages of both in the Democratic Republic of the Congo in 2024.
Key facts
| Transmission | Close physical contact with lesions, body fluids, contaminated materials, and respiratory secretions during close contact; animal-to-human spread also occurs. WHO reported sexual contact as the main driver in the 2022 global outbreak and documented sustained human-to-human clade I transmission in eastern Democratic Republic of the Congo in 2024. |
|---|---|
| Incubation | unknown |
| Case fatality | Varies by outbreak and setting. WHO reported 4.5% in Democratic Republic of the Congo in 2023, 4.9% there in 2024 as of 2024-05-26, and 15% in South Africa in 2024 (3 deaths among 20 confirmed cases). |
| Reproduction number | unknown |
| Vaccine | Vaccines exist, but access is uneven; WHO reported lack of vaccines in the Democratic Republic of the Congo in 2024. |
| Treatment | Mainly supportive care; antiviral treatment exists in some settings, but WHO reported insufficient treatment kits in the Democratic Republic of the Congo in 2024. |
| Reservoir | Animal reservoir is not fully confirmed; reviews describe mpox as a zoonosis and note reservoir(s) remain unconfirmed. |
| Endemic regions | Historically in parts of West, Central, and East Africa; WHO reported endemic provinces in the Democratic Republic of the Congo and global spread since 2022. |
Transmission
Mpox spreads through close contact. That includes direct contact with a person’s skin lesions or sores, body fluids, and contaminated items such as bedding or clothing. Respiratory spread can also happen during close face-to-face contact, but the sources here stress close contact rather than easy long-range airborne spread. Animal-to-human infection is also part of mpox epidemiology, which is why it is called a zoonotic disease. Transmission patterns can change by outbreak. WHO said the global clade IIb outbreak since 2022 was mainly driven by sexual contact among men who have sex with men. WHO also reported that in eastern Democratic Republic of the Congo, a clade I outbreak showed sustained human-to-human transmission from 2023 into 2024, with sexual contact and other close physical contact involved. A 2023 review also found evidence that viable virus can be found on high-touch surfaces, so shared items may matter in some settings.
- Mpox - Democratic Republic of the Congo WHO · 14 Jun 2024
- Transmission of monkeypox/mpox virus: A narrative review of environmental, viral, host, and population factors in relation to the 2022 international outbreak. Europe PMC · 1 Feb 2023
- Mpox Person-to-Person Transmission-Where Have We Got So Far? A Systematic Review. Europe PMC · 28 Apr 2023
- Pathogenicity and virulence of monkeypox at the human-animal-ecology interface. Europe PMC · 1 Dec 2023
Symptoms and severity
Mpox often causes a rash or sores plus fever and swollen lymph nodes. The rash can blister and then crust over. Some people also have headache, pain when swallowing, pain on urination, or genital lesions; WHO described those features in a 2024 case from the Democratic Republic of the Congo. Severity varies a lot. Many people recover, but severe illness can happen, especially in children, pregnant people, and people with weakened immune systems. WHO highlighted that infants and children under five years were at highest risk of severe disease and death in the Democratic Republic of the Congo in 2024. The reported case fatality rate also differs by place and outbreak. WHO reported 654 deaths among 14,626 mpox cases in the Democratic Republic of the Congo in 2023, a 4.5% case fatality rate, and 384 deaths among 7,851 cases there in 2024 as of 2024-05-26, a 4.9% rate. In South Africa, WHO reported 3 deaths among 20 confirmed cases in 2024.
- Mpox - Democratic Republic of the Congo WHO · 14 Jun 2024
- Mpox – South Africa WHO · 9 Jul 2024
- Mpox (monkeypox) - Democratic Republic of the Congo WHO · 23 Nov 2023
- Mpox Wikipedia
Treatment and vaccines
Care for mpox is often supportive. That means treating pain, keeping skin lesions clean, helping with fluids and nutrition, and treating complications. Specific antiviral treatment and vaccination are part of the response in some countries, but access is uneven. WHO said the Democratic Republic of the Congo faced insufficient treatment kits and a lack of vaccines in 2024 even as cases spread to more provinces. That matters because severe disease is more likely in young children and in people with weakened immune systems. Reviews in the medical literature discuss treatment and prevention, but the sources returned here do not give one simple number for how well treatment works across all settings. The safest public message is that tools exist, but they are not available everywhere and should not be assumed to be easy to get during an outbreak. For worried readers, the practical point is early medical assessment, especially for severe pain, trouble swallowing, eye symptoms, dehydration, pregnancy, or immune suppression.
- Mpox - Democratic Republic of the Congo WHO · 14 Jun 2024
- Monkeypox: epidemiology, pathogenesis, treatment and prevention. Europe PMC · 2 Nov 2022
- Availability, scope and quality of monkeypox clinical management guidelines globally: a systematic review. Europe PMC · 1 Aug 2022
- Monkeypox (mpox) in immunosuppressed patients. Europe PMC · 2 Feb 2023
Where it occurs
Mpox has long been reported in parts of West, Central, and East Africa, especially in forested areas, but since 2022 it has also spread widely outside those regions. WHO described the Democratic Republic of the Congo as the country reporting the highest number of cases in the WHO African Region, with endemic transmission in multiple provinces and spread into new areas. By November 2023, WHO said 22 of the country’s 26 provinces had reported cases, and by mid-2024 a new case in North Kivu raised that to 23 of 26 provinces. Outside Africa, the site archive shows the 2022 global outbreak reached many countries, with WHO’s global situation page listing about 87,000 cases and 140 deaths in that event. WHO also reported the first clade Ib case outside the African Region in Sweden in 2024 after travel to an affected African country. So mpox is no longer only a disease of one region, even though the heaviest burden remains in parts of Africa.
- Mpox (monkeypox) - Democratic Republic of the Congo WHO · 23 Nov 2023
- Mpox - Democratic Republic of the Congo WHO · 14 Jun 2024
- Mpox - Sweden WHO · 30 Aug 2024
- Global mpox outbreak Reference · 6 May 2022
Recent history
This site’s archive lists 20 mpox-related events since 1997. Early WHO notices were centered on the Democratic Republic of the Congo and other African countries. Later reports included Nigeria, Cameroon, Singapore, the United Kingdom, and the United States. The turning point was 2022, when WHO reported a multi-country outbreak in countries that had not previously reported mpox and later tracked a global outbreak with about 87,000 cases and 140 deaths in the archive summary. Since then, WHO has reported a new phase centered on clade I in Africa. In 2023, WHO described a sharp rise in cases in the Democratic Republic of the Congo and spread into new provinces. In 2024, WHO reported sustained community transmission of clade I in eastern Democratic Republic of the Congo, a 2024 public health emergency of international concern focused on the African Region, cases in South Africa, and the first clade Ib case reported outside Africa in Sweden. In 2025 and early 2026, WHO notices pointed to broader clade Ib transmission and two reported recombinant cases linked to travel.
- 1997 - Monkeypox in the Democratic Republic of the Congo (former Zaire) WHO Disease Outbreak News · 21 Mar 1997
- Multi-country monkeypox outbreak in non-endemic countries WHO Disease Outbreak News · 21 May 2022
- Global mpox outbreak Reference · 6 May 2022
- Mpox (monkeypox) - Democratic Republic of the Congo WHO · 23 Nov 2023
What to watch
Several signals would make mpox more concerning. One is spread into new regions or steady local transmission in places that previously only saw travel-related cases. WHO flagged that in Sweden in 2024 and later reported broader clade Ib transmission in all WHO regions in 2025. Another is clearer evidence of sustained human-to-human spread, especially where animal exposure is not involved; WHO documented that in eastern Democratic Republic of the Congo. A third warning sign is rising severity, such as more illness in very young children, more deaths, or more severe disease in people with HIV or other immune suppression. Problems with diagnosis also matter: WHO said a new clade I variant in the Democratic Republic of the Congo had gene deletions that affect diagnostics. Finally, shortages of vaccines or treatment kits can let outbreaks grow even when tools exist. WHO explicitly reported lack of vaccines and insufficient treatment kits in the Democratic Republic of the Congo in 2024.
- Mpox - Democratic Republic of the Congo WHO · 14 Jun 2024
- Mpox - Sweden WHO · 30 Aug 2024
- Broader transmission of mpox due to clade Ib MPXV – Global situation WHO · 5 Dec 2025
- Monkeypox (mpox) in immunosuppressed patients. Europe PMC · 2 Feb 2023
Related outbreaks
- Mpox (clades I and II) Attention: elevated